CN101637558B

CN101637558B - Medicament for treating thrombocytolytic purpura

Info

Publication number: CN101637558B
Application number: CN200910094942XA
Authority: CN
Inventors: 李忠能
Original assignee: Individual
Current assignee: Individual
Priority date: 2009-09-07
Filing date: 2009-09-07
Publication date: 2011-06-15
Anticipated expiration: 2029-09-07
Also published as: CN101637558A

Abstract

The invention provides a medicament for treating thrombocytolytic purpura, which comprises the following raw materials by weight part: 15-25 parts of rhizoma smilacis glabrae, 20-30 parts of honeysuckle, 10-20 parts of radix arnebiae seu lithospermi, 10-20 parts of rehmannia root, 10-20 parts of white mulberry root-bark, 25-35 parts of oyster, 10-20 parts of clerodendrum bungei, 10-20 parts of yellow celery and 5-15 parts of cicada slough. In the invention, the natural herbal drugs capable of clearing away heat and toxic materials, activating blood and dissolving stasis, cooling and nourishing blood and stopping bleeding, removing water and eliminating swellings are selected from the medicinal treasury of China, and play roles of clearing away heat, cooling the blood, stopping the bleeding, eliminating spots, activating blood and dissolving stasis, improving the microcirculation, dredging channels, diminishing pain, and the like according to a Chinese medicine theory formula. The medicament does not contain any chemical drugs, thereby being innoxious to human bodies; and the medicament is convenient to take, can enhance the resistance and the immunity of organisms and relieve pains of patients, and has obvious curative effect.

Description

A kind of medicine for the treatment of thrombocytopenic purpura

Technical field

The present invention relates to a kind of medicine, especially a kind of Chinese medicine for the treatment of thrombocytopenic purpura belongs to biological technical field.

Background technology

Thrombocytopenic purpura be with PA hemorrhage in common a kind of, clinical manifestation is dermatorrhagia (if any petechia in blocks and an ecchymosis), mucosal bleeding (as nose, gingiva and oral hemorrhage), visceral hemorrhage (hemorrhage) as gastrointestinal tract and urinary system, reproductive system.The laboratory feature still has the bleeding time to prolong except that platelet reduces, and clot retraction is bad and capillary fragility test is positive.This disease is divided into two kinds of constitutional and Secondary cases.Constitutional (promptly agnogenic) thrombocytopenic purpura, pilosity is born in child and teenager, is many with young women.The generation of primary disease is relevant with immunity, and spleen also plays an important role to hematoblastic destruction.This patient's blood plasma then can make normal person's thrombocytopenia as being defeated by the normal person, even purpura occurs; Normal person's blood plasma is defeated by the patient, and the result can make the platelet in the new blood plasma be destroyed rapidly.The treatment of primary disease with the control over bleeding phenomenon, to reduce hematoblastic destruction, improve hematoblastic generation situation be main means.Though doctor trained in Western medicine can be stopped blooding as early as possible, be difficult to eliminate the blood stasis ecchymosis, can't effect a radical cure.

Theory of Chinese medical science thinks that this disease is by taste imbalance of YIN and YANG institute extremely.Existing commercially available Chinese medicine is because of existing the human body individual variation bigger, and the somebody is suitable for, and the somebody then is difficult to be suitable for, even does not have effect, therefore, is difficult to generally obtain ideal therapeutic effect.

Summary of the invention

The object of the present invention is to provide a kind of medicine for the treatment of thrombocytopenic purpura, to satisfy such patient's treatment.

The present invention realizes by following technical proposal: a kind of medicine for the treatment of thrombocytopenic purpura is characterized in that being made up of the raw material of following mass parts:

15～25 parts of Rhizoma Smilacis Glabraes

20～30 parts of Flos Loniceraes

10～20 parts of Radix Arnebiae (Radix Lithospermi)s

10～20 parts of Radix Rehmanniae

10～20 parts of Cortex Mori

25～35 parts of Concha Ostreaes

10～20 parts of Caulis et folium clerodendri bungeis

10～20 parts of Radix Scutellariaes (Radix Scutellariae)

5～15 parts of Periostracum Cicadaes.

Wherein, the Rhizoma Smilacis Glabrae slightly sweet flavor is put down, and has the effect in detoxifcation, dehumidifying, sharp joint; The Flos Lonicerae nature and flavor are sweet, and are cold, go into lung, stomach warp, have heat clearing away, antidotal effect; Radix Arnebiae (Radix Lithospermi) nature and flavor bitter cold, GUIXIN, Liver Channel have removing heat from blood, invigorate blood circulation, heat clearing away, antidotal effect; Radix Rehmanniae (also claiming the Radix Rehmanniae) nature and flavor are sweet, bitter, cool, go into the heart, liver, kidney channel, the energy nourishing YIN and benefiting blood; The Cortex Mori nature and flavor are sweet, cold, go into lung, spleen channel, have the effect of eliminating pathogen from the lung for relieving asthma, line water detumescence; The Concha Ostreae nature and flavor are salty and bitter, and liver, kidney channel are gone in cold, have yin fluid astringing, YANG hyperactivity suppressing, hidroschesis, arresting seminal emission, reduce phlegm, the effect of softening the hard mass; Caulis et folium clerodendri bungei nature and flavor suffering, temperature have the effect of promoting blood circulation to remove blood stasis, subduing swelling and detoxicating; Periostracum Cicadae (also claim Periostracum Cicadae, Cicadae move back, cicada skin) is animal cicada Cryptotympana atrata Fabr., and its nature and flavor suffering, sweet, cool is gone into lung, liver, spleen channel, have relieve internal heat anticancer, the effect of expelling wind to relieve convulsion; Radix Scutellariae (Radix Scutellariae) nature and flavor hardship, cold is gone into the heart, lung, gallbladder, large intestine channel, has the removing the relative excess fire, except that damp and hot, and the hemostatic effect.

The medicine production method of treatment thrombocytopenic purpura provided by the invention is:

(1) above-mentioned whole components are mixed according to the above ratio after, with conventional decocting 2-3 time, merge decocting liquid, after conventional sterilization treatment, canned oral formulations.

(2) above-mentioned whole components are mixed according to the above ratio after, use conventional method, through water logging bubble, extraction, filtration, so repeat 2-3 time, merging filtrate, through conventional method concentrate, dry water extract, be processed into any preparations such as pharmaceutically acceptable tablet, capsule, powder, pill, electuary through the conventional adjuvant that conventional method is allocated conventional amount used into again.

(3) above-mentioned whole components are mixed according to the above ratio after, use conventional method, through ethanol lixiviate, extraction, filtration, ethanol reclaims, so repeat 2-3 time, merge extractive liquid,, through conventional method concentrate, dry ethanol extract, be processed into any preparations such as pharmaceutically acceptable tablet, capsule, powder, pill, electuary through the conventional adjuvant that conventional method is allocated conventional amount used into again.

Above-mentioned solution of the present invention is based on pathogenetic understanding and the Therapeutic Principle of China's Chinese medicine to thrombocytopenic purpura, with reference to the modern pharmacological research achievement, from medical treasure-house, filter out heat clearing away, detoxifcation, promoting blood circulation to remove blood stasis, removing heat from blood, nourish blood, the above-mentioned natural plant of hemostasis, line water detumescence, by the theory of Chinese medical science prescription, make its performance clearing away heat and cooling blood, the hemostasis dissipating rashes, promoting blood circulation to remove blood stasis, microcirculation improvement, dredging the meridian, effects such as eliminate pain.

Medicine of the present invention shows that through clinical use result following advantage is arranged: all adopting natural plant is principal agent, does not add any chemicals, nontoxic to human body, taking convenience, energy enhancing body resistance and immunity, remove the patient suffering, therapeutic effect is remarkable.

The specific embodiment

Below in conjunction with embodiment the present invention is described further.

Embodiment 1

By following proportioning get the raw materials ready (kg):

Rhizoma Smilacis Glabrae 15, Flos Lonicerae 20, Radix Arnebiae (Radix Lithospermi) 10, Radix Rehmanniae 10, Cortex Mori 10, Concha Ostreae 25, Caulis et folium clerodendri bungei 10, Radix Scutellariae (Radix Scutellariae) 10, Periostracum Cicadae 5;

The following method of process: after above-mentioned whole components mixing, use conventional method, through water logging bubble, extraction, filtration, so repeat 3 times, merging filtrate, through conventional method concentrate, after the drying, after routine is pulverized, incapsulate in the shell, promptly get the capsule for the treatment of thrombocytopenic purpura.

Embodiment 2

By following proportioning get the raw materials ready (kg):

Rhizoma Smilacis Glabrae 20, Flos Lonicerae 25, Radix Arnebiae (Radix Lithospermi) 15, Radix Rehmanniae 15, Cortex Mori 15, Concha Ostreae 30, Caulis et folium clerodendri bungei 15, Radix Scutellariae (Radix Scutellariae) 15, Periostracum Cicadae 10;

Through following method: after above-mentioned whole components were mixed, conventional decocting 2-3 time merged decocting liquid, after conventional sterilization treatment, and must oral liquid formulations.

Embodiment 3

By following proportioning get the raw materials ready (kg):

Rhizoma Smilacis Glabrae 25, Flos Lonicerae 30, Radix Arnebiae (Radix Lithospermi) 20, Radix Rehmanniae 20, Cortex Mori 20, Concha Ostreae 35, Caulis et folium clerodendri bungei 20, Radix Scutellariae (Radix Scutellariae) 20, Periostracum Cicadae 15;

Through following method: after above-mentioned whole components are mixed, use conventional method, through ethanol lixiviate, extraction, filtration, ethanol reclaims, and so repeats merge extractive liquid, 2 times, through conventional method concentrate, dry alcohol-extracted extract, be processed into tablet through the conventional adjuvant that conventional method is allocated conventional amount used into again.

For showing the therapeutic effect of medicine of the present invention to thrombocytopenic purpura, the present invention is through 38 routine clinical observations, its basic condition is: 38 routine patients' medical history, the state of an illness, age, sex and former Therapeutic Method are suitable, and all be the thrombocytopenic purpura patient who makes a definite diagnosis through local hospital, these patients are after using original therapeutic scheme invalid, just stop using original therapeutic scheme, and change clothes medicine provided by the invention.These patients' symptom index of correlation in blood is in the improper scope (seeing Table the assay hurdle before taking medicine in 1 the clinical blood index of correlation), and there are symptoms such as blood stasis, ecchymosis, muscle and neuralgia, anasarca, inconvenient activity in various degree in all patients.

Method of administration: take the oral liquid medicine three times of embodiment 2 every day, each dosage is looked different patients and is determined that specifically taking medicine 10 days is a course of treatment, takes medicine altogether and observes 30 days, and its result is as follows:

The clinical blood index of correlation changes: the variation of clinical blood index of correlation sees Table 1 before and after taking medicine of the present invention.As can be seen from Table 1, take the present invention after, the index of correlation that is higher or lower than range of normal value in the blood has all had obvious improvement, the medicine that proves the present invention is effective.

Other symptom variation: among the 38 routine patients, have 20 people's symptoms such as blood stasis, ecchymosis, muscle and neuralgia, anasarca, inconvenient activity all to disappear, through sampling survey subsequently, more than 2 years all the end see recurrence.There are 10 people's symptoms such as blood stasis, muscle and neuralgia, anasarca, inconvenient activity all to disappear, but still have a small amount of ecchymosis to exist, but all have not big harm, do not influence living and studying.Though there are 5 people's anasarcies to eliminate, activity still has blood stasis, ecchymosis to exist freely, and muscle and nerve also pain can occur frequently.Then DeGrain of 3 people is arranged.

The clinical blood index of correlation changed before and after table 1 was taken medicine of the present invention

Claims

1. medicine for the treatment of thrombocytopenic purpura is characterized in that being made up of the raw material of following mass parts:

15～25 parts of Rhizoma Smilacis Glabraes

20～30 parts of Flos Loniceraes

10～20 parts of Radix Arnebiae (Radix Lithospermi)s

10～20 parts of Radix Rehmanniae

10～20 parts of Cortex Mori

25～35 parts of Concha Ostreaes

10～20 parts of Caulis et folium clerodendri bungeis

10～20 parts of Radix Scutellariaes

5～15 parts of Periostracum Cicadaes.